Abstract
SummaryFebrile neutropenia (FN) is a common oncologic emergency where quick patient assessment and prompt initiation of antimicrobial treatment is crucial. Guidelines provide detailed recommendations on prevention and treatment; however, their real-world implementation can prove to be difficult. Score systems for outcome risk are effective in identifying low-risk patients with FN. After initiation of therapy, regular re-evaluation of antimicrobial treatment is necessary, and further diagnostic studies should be tailored to each patient. Use of granulocyte colony-stimulating factor (G-CSF) prophylactically in chemotherapy regimens with intermediate FN risk as well as therapeutically in patients with manifest FN is variable in clinical practice and needs to be better defined. Future steps of reducing risk of FN involve investigating underlying genetic factors. Regarding early detection of FN, patient education is paramount. This short review gives an overview of current guidelines and highlights key challenges in management of FN.
Funder
Medical University of Vienna
Publisher
Springer Science and Business Media LLC
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Supportive management;memo - Magazine of European Medical Oncology;2023-12